Jumbo Drug Bank’s JDB153 Enters Phase I Trial for Advanced Solid Tumors
Data from Fineline Cube indicates that JDB153, a potential first-in-class (FIC) small-molecule inhibitor targeting Mnk...
Potential first-in-class
Sichuan Kelun’s KL340399 Wins NMPA Approval for Solid Tumor Trials
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced receiving clinical trial approval from the...
Jiangsu Hengrui Medicine’s SHR4640 Receives NMPA Approval for Gout Trial
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced receiving approval from the National...
Alphamab Oncology Doses First Patient in Phase I Trial for PD-L1/OX40 Bispecific Antibody KN052
China-based Alphamab Oncology (HKG: 9966) has announced the dosing of the first patient in a...